MondegarAI
Birchview Capital, LP

Q4 2025 · 13F-HR

Birchview Capital, LPholdings as filed

Filed 2026-02-13 · accession 0001618205-26-000001

$170.8M
Reported value
68
Positions
2025-12-31
Period end
View analyzed profile →PRO

The Brief · Birchview Capital, LP · Q4 2025

AI · grounded in 13F

Birchview Capital, LP established a new position in LRCX valued at $6.9M. The fund also increased its holdings in PHAT by 129.4% and CMPX by 82.5%. On the sell side, the fund closed its position in AXGN, reducing its exposure by $2.1M.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
482480100KLACKLA CORPORATION$26.6M15.6%21,883CommonSOLE
110122108BMYBRISTOL-MYERS SQUIBB CO$16.3M9.56%302,842CommonSOLE
20454B104CMPXCOMPASS THERAPEUTICS INC$8.6M5.01%1,592,938CommonSOLE
86150R107STOKSTOKE THERAPEUTICS INC$8.3M4.83%260,000CommonSOLE
512807306LRCXLAM RESEARCH CORPORATION$6.9M4.04%40,329CommonSOLE
68062P106OLMAOLEMA PHARMACEUTICALS INC$6.7M3.94%269,000CommonSOLE
86366E106GPCRSTRUCTURE THERAPEUTICS INC$6.3M3.66%90,000CommonSOLE
74366E102PTGXPROTAGONIST THERAPEUTICS INC$4.8M2.81%55,000CommonSOLE
004225108ACADACADIA PHARMACEUTICALS INC$4.6M2.67%171,000CommonSOLE
69047Q102OVVOVINTIV INC$4.2M2.47%107,500CommonSOLE
G72800108PRTAPROTHENA CORP PLC$4.2M2.47%441,019CommonSOLE
83422E204SLDBSOLID BIOSCIENCES INC$4.0M2.33%705,955CommonSOLE
64125C109NBIXNEUROCRINE BIOSCIENCES INC$3.9M2.26%27,190CommonSOLE
03152W109AM6AMICUS THERAPEUTICS INC$3.6M2.11%253,000CommonSOLE
088786108BCYCBICYCLE THERAPEUTICS PLC$3.3M1.92%462,700CommonSOLE
71722W107PHATPHATHOM PHARMACEUTICALS INC$3.2M1.89%195,000CommonSOLE
14843C105CSTLCASTLE BIOSCIENCES INC$3.1M1.84%80,600CommonSOLE
45826J105NTLAINTELLIA THERAPEUTICS INC$2.8M1.66%315,400CommonSOLE
45257U108IMNMIMMUNOME INC$2.8M1.63%130,000CommonSOLE
218352102CORTCORCEPT THERAPEUTICS INC$2.3M1.37%67,200CommonSOLE
92337R101VERAVERA THERAPEUTICS INC$2.2M1.30%44,000CommonSOLE
74838J101QDELUSDQUIDELORTHO CORP$2.1M1.21%72,548CommonSOLE
G6674U108NVCRNOVOCURE LTD$2.0M1.15%152,100CommonSOLE
09075X108BDSXBIODESIX INC$2.0M1.14%286,804CommonSOLE
23282W605CYTKCYTOKINETICS INC$1.9M1.12%30,000CommonSOLE
71944F106PHRPHREESIA INC$1.9M1.10%110,700CommonSOLE
26884L109EQTEQT CORPORATION$1.9M1.09%34,619CommonSOLE
415858109HROWHARROW HEALTH INC$1.7M0.98%34,000CommonSOLE
89422G107TVTXTRAVERE THERAPEUTICS INC$1.6M0.96%43,000CommonSOLE
344174107FHTXFOGHORN THERAPEUTICS INC$1.5M0.89%281,730CommonSOLE
91307C102UTHRUNITED THERAPEUTICS CORP$1.5M0.86%3,000CommonSOLE
90400D108RAREULTRAGENYX PHARMACEUTICAL INC$1.4M0.83%62,000CommonSOLE
G01767105ALKSALKERMES PLC$1.4M0.82%50,000CommonSOLE
640268306NKTRNEKTAR THERAPEUTICS$1.3M0.77%31,000CommonSOLE
03770N101APGEAPOGEE THERAPEUTICS INC$1.2M0.71%16,000CommonSOLE
92337C203VSTMVERASTEM INC$1.2M0.68%150,000CommonSOLE
05464T104AXSMAXSOME THERAPEUTICS INC$1.1M0.65%6,061CommonSOLE
574795100MASIMASIMO CORP$1.1M0.63%8,280CommonSOLE
88025U109TXG10X GENOMICS INC$962,2900.56%59,000CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$941,2200.55%21,000CommonSOLE
69404D108PACBPACIFIC BIOSCIENCES OF CALIFORNIA INC$935,0000.55%500,000CommonSOLE
483497103KALVKALVISTA PHARMACEUTICALS INC$920,5500.54%57,000CommonSOLE
35671D857FCXFREEPORT-MCMORAN CL-B$916,5770.54%18,046CommonSOLE
92332V107VTYXUSDVENTYX BIOSCIENCES INC$910,4680.53%100,827CommonSOLE
N69605108PHVSPHARVARIS N V$828,2540.48%29,847CommonSOLE
452327109ILMNILLUMINA INC$786,9600.46%6,000CommonSOLE
N90064101QUREUNIQURE NV$736,7810.43%30,789CommonSOLE
40637H109HALOHALOZYME THERAPEUTICS INC$679,7300.40%10,100CommonSOLE
G11196105BIOHAVEN LTD$670,2310.39%59,365CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$664,5450.39%8,688CommonSOLE
89455T109TMCITREACE MEDICAL CONCEPTS INC$556,0200.33%226,947CommonSOLE
745848101LUNGPULMONX CORP$553,7660.32%250,573CommonSOLE
75382E208RAPTRAPT THERAPEUTICS INC$508,0500.30%15,000CommonSOLE
38341P102GOSSGOSSAMER BIO INC$428,3460.25%138,176CommonSOLE
02081G201ATECALPHATEC HOLDINGS INC$379,9400.22%18,058CommonSOLE
690145107OMGBPOUTSET MEDICAL INC$366,9670.21%98,913CommonSOLE
03753U106APLSUSDAPELLIS PHARMACEUTICALS INC$351,6800.21%14,000CommonSOLE
53635D202LQDALIQUIDIA TECHNOLOGIES INC$344,9000.20%10,000CommonSOLE
137404109CADLCANDEL THERAPEUTICS INC$339,0000.20%60,000CommonSOLE
92915B106VYGRVOYAGER THERAPEUTICS INC$294,4280.17%74,918CommonSOLE
896442308TRINTRINITY CAP INC$293,0000.17%20,000CommonSOLE
45720N103INBXINHIBRX BIOSCIENCES INC$292,1420.17%3,698CommonSOLE
48662X105KBDCKAYNE ANDERSON BDC INC$286,4000.17%20,000CommonSOLE
230031106CGEMCULLINAN THERAPEUTICS INC$207,0000.12%20,000CommonSOLE
05479K106ELUTELUTIA INC$182,1930.11%263,018CommonSOLE
022307102ALMSALUMIS INC$97,6000.06%10,000CommonSOLE
256086109DCGODOCGO INC$43,8090.03%49,908CommonSOLE
98943L107ZNTLZENTALIS PHARMACEUTICALS INC$22,9500.01%17,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.